Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Medytox is a biopharmaceutical company specializing in the development of novel therapeutics for rare diseases. Our primary pipeline candidate is Udenafil, a treatment for Fontan-associated pulmonary hypertension (FAPH) in patients with single-ventricle heart disease. Udenafil is currently in clinical development, and we are targeting global market entry.
메지온은 희귀질환 치료제 개발에 주력하는 신약 개발 전문 제약회사입니다. 주요 파이프라인은 단심실 심장병 환자의 폰탄 관련 폐고혈압(FAPH) 치료를 위한 유데나필(Udenafil)입니다. 현재 임상 단계에 있으며, 글로벌 시장 진출을 목표로 하고 있습니다.
